The glial glutamate transporter EAAT2 is primarily responsible for clearance of glutamate from the synaptic cleft and loss of EAAT2 has been previously reported in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The loss of functional EAAT2 could lead to the accumulation of extracellular glutamate resulting in cell death known as excitotoxicity.
INTRODUCTION
Excitatory neurotransmission in the mammalian central nervous system (CNS) is mediated in large part by glutamate. Overactivation of glutamatergic neurons can result in a neurodegenerative process known as excitotoxicity (1) . Excitotoxic cell death can occur in the immature as well as the mature CNS and shares features with both apoptosis and necrosis (2) (3) .
Excitotoxicity has been implicated as the mechanism of neuronal damage resulting from acute insults such as stroke, epilepsy and trauma as well as during the progression of adult-onset neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Huntington's disease (4) .
ALS is a fatal neuromuscular disorder that is characterized by progressive motor dysfunction resulting from selective degeneration of cortical motor neurons and spinal motor neurons.
Familial ALS (FALS) accounts for 5-10% of all reported cases of ALS and demonstrates an
autosomal dominant pattern of inheritance (5) (6) . About 25% of the cases of FALS are linked to mutation in gene encoding the antioxidant enzyme Cu 2+ /Zn 2+ superoxide dismutase (SOD1).
Over 90 distinct familial SOD1 mutations have been found to date (7) . Overexpression of some of these ALS-linked mutant SOD1 proteins (i.e. G93A, G37R and G85R) in transgenic mice results in the development of a neurological disorder that resembles ALS (8) (9) (10) . Several studies have demonstrated that mutant SOD1 causes motor neuron degeneration by acquiring a toxic gain of function property rather than by the loss of enzymatic activity (9, 11, 12) . The molecular mechanisms underlying mutant SOD1-linked FALS remain unclear.
Glutamate mediated excitotoxicity is postulated to play a major role in motor neuron degeneration (13) . Glutamate is normally cleared from the synaptic space by a family of Na has been shown to be the main mediator of glutamate clearance (15) . Early studies showed an increase in the concentration of glutamate in the cerebrospinal fluid of patients with ALS as well as a defect in glutamate transport activity in the motor cortex and spinal cord of ALS patients (16, 17) . A selective loss of EAAT2 was found in affected regions within the CNS of ALS patients (18) . Interestingly, numerous abnormally spliced EAAT2 mRNAs have been identified from the affected areas of ALS patients and the expression of these abnormally spliced RNA species correlated with the loss of EAAT2 protein in ALS (19) .
The loss of EAAT2 expression and function is not unique to ALS. Defective glutamate transport and loss of EAAT2 protein have also been observed in affected brain regions of
Alzheimer's disease patients (20) (21) . The expression of EAAT2 was reduced in an agedependent manner in a mouse model for Huntington's disease (22) . However, at present, it is unknown whether loss of functional EAAT2 is the initial mechanism which leads to neuron degeneration or if this loss is secondary to cell death. These issues cannot be easily addressed from human studies. However, the loss of EAAT2 has also been observed in transgenic models of mutant SOD1-mediated ALS (23) (24) (25) . In SOD1(G93A) transgenic mice, EAAT2 protein is progressively decreased in the ventral, but not in the dorsal, horn of the lumbar spinal cord (24) .
This effect was specifically found in 14-and 18-week-old mice that had motor function impairment, motor neuron loss and reactive astrocytosis. No changes in EAAT2 were observed before the appearance of clinical symptoms. In this study we attempt to supplement the loss of EAAT2 with transgenic EAAT2 and ask whether it can protect neurons from glutamate-induced injury. We generated transgenic mouse lines that express human EAAT2 under the control of the human glial fibrillary acidic protein (GFAP) promoter and then crossed these transgenic mice with SOD1(G93A) transgenic mice. Our EAAT2/SOD1(G93A) double transgenic mice showed a delay in motor neuron degeneration and the associated motor function at early stage of disease progression but no change in life span when compared to their SOD1(G93A) littermates.
RESULTS

Generation and establishment of c-Myc-hEAAT2 transgenic founder mice
We generated transgenic mice expressing human EAAT2 (hEAAT2) under the control of the human glial fibrillary acidic protein (hGFAP) promoter. The GFAP promoter was used in this study because (1) EAAT2 is predominantly expressed in astrocyte and (2) decreases in EAAT2
are accompanied by increased GFAP levels in SOD1(G93A) mice (24); the lost EAAT2, therefore, can be supplemented with transgenic hEAAT2. The transgene construct is diagramed in Figure 1A . The 2.2-kb GFAP promoter region has been previously shown to drive high levels of reporter gene expression predominantly in astrocytes beginning during the middle stage of prenatal development and continuing into adulthood (26) (27) . A c-Myc epitope tag was placed on N-terminus of hEAAT2 so as to permit detection of transgenic hEAAT2 expression. Transient expression of pcDNA3/c-Myc-hEAAT2 in HEK293 cells showed that the presence of the Nterminal c-Myc epitope tag did not affect the expression, localization and function of hEAAT2 (data not shown). A segment of the mouse protamine-1 (MP1) gene containing an intron and a polyadenylation site was placed on the 3' end of hEAAT2 cDNA so as to increase expression of the transgene (28) .
The hGFAP-c-Myc-hEAAT2 transgene construct was injected into mouse eggs, which DNA with PstI which produces a 1,295 bp (from +425 to +1719 of the hEAAT2 cDNA) band in transgenic mice. As shown in Figure 1B , the relative transgene copy numbers differed for each line varying from <5 to 50. The lines 7 and 22 carried more copies of transgene than the other transgenic F0 mice.
Among these 31 F0 pups, 3 pups were significantly smaller than others. Interestingly, the three smaller mice (#19, 22, and 32) were transgenic and carried higher copy numbers of the transgene than the other transgenic mice. These three mice died prematurely (#32, 3 weeks; #19, 2 months and #22, 6 months) compared to the other transgenic F0 mice. The #19 female mouse produced one litter and the #22 male mouse produced three litters before dying. They produced fewer pups per litter (2-4) and either none or a few of the resultant pups were transgenic. All of the resultant F1 transgenic pups were unusually small. Of all of the transgenic F1 pups produced from the #22 male founder mouse, only one pup survived to reproductive age. This mouse was then used to maintain the #22 line. We also examined embryos at different developmental stages from the #22 male transgenic mouse. More than 80 % of these embryos carried the transgene indicating that the transgene integrated into multiple chromosomes in the # 22 mouse. Before E14.5, the number and the size of embryos were normal (n=12-16 per litter). However, after E14.5, abnormal embryos were observed and the numbers of embryos were dramatically decreased. Interestingly, GFAP expression has been shown to significantly increase from E14.5 (26) (27) . It is possible that overexpression of EAAT2 may be lethal during embryonic development.
RT-PCR and immunoblot analyses were carried out to determine c-Myc-hEAAT2 transgene expression in each line using non-transgenic littermates as negative controls. RT-PCR results
showed that c-Myc-hEAAT2 mRNA could only be detected in line 7 and line 22 (Fig. 1C) .
Quantitative immunoblot analysis of c-Myc-hEAAT2 protein expression in whole brain extracts of transgenic mice as well as their non-transgenic littermates was performed using antibodies against the C-terminus of EAAT2. We could not detect transgenic protein expression by immunoblot analysis using antibodies against the c-Myc epitope tag (the possible reasons are discussed in the discussion section); however, these antibodies could detect transgene protein by immunohistochemistry (see below, Fig. 2B ). The results (Fig. 1D) showed that increased EAAT2
protein expression in line 7 (2.2-fold) and line 22 (1.8-fold) mice but not in those lines which contain fewer copies of the transgene when compared to non-transgenic littermates. There was no difference in SOD1 protein expression between transgenic and non-transgenic mice.
Expression and localization of c-Myc-hEAAT2 protein in transgenic mice
We determined the expression profile of the c-Myc-hEAAT2 protein in different tissues of adult (2 months) transgenic and nontransgenic littermate mice. c-Myc-hEAAT2 protein could be detected in the brain and spinal cord ( Fig. 2A) but not in peripheral tissues such as the kidney, heart and lung (data not shown). Overexpression of c-Myc-hEAAT2 did not alter the protein levels of other glutamate transporters such as EAAT1 or EAAT3 nor SOD1 in the CNS ( Fig. 2A shows EAAT1 and SOD1immunoblotting results and EAAT3 is not shown). The localization of c-Myc-hEAAT2 within the CNS was examined in transgenic and non-transgenic mice using antibodies against EAAT2 as well as the c-Myc epitope tag. Increased EAAT2 and c-Myc immunoreactivities were observed in both the brain (data not shown) and spinal cord (Fig. 2B ) of transgenic mice when compared to non-transgenic littermates.
In order to verify that c-Myc-hEAAT2 was properly expressed on the surface of transgenic mouse astrocytes, we performed cell surface biotinylation experiments on cortical primary dissociated cultures derived from c-Myc-hEAAT2 transgenic mice as well as from nontransgenic littermates. The cultures were incubated either with biotin-7-NHS (Bt) or with buffer alone (Non)
followed by cell lysis. The resultant lysates were subjected to avidin affinity chromatography and the avidin-bound proteins (B) as well as the unbound proteins (FT) were analyzed for EAAT2
and SOD1 (a marker for intracellular proteins) locations by immunoblotting. Those proteins which were retained on an avidin column are considered to be the cell surface proteins while the unbound proteins are the intracellular proteins. As shown in Figure 2C , EAAT2 was primarily located at the cell surface fraction (Bt) and there was a strong increase (~2.5-fold) in cell surface EAAT2 in transgenic cultures when compared to nontransgenic cultures. The cytosolic protein SOD1 was only found in the intracellular fractions.
Subcellular fractionation was performed to determine if c-Myc-hEAAT2 is properly localized to the plasma membrane in vivo. Transgenic and nontransgenic mouse forebrain homogenates (H) were fractionated into plasma membrane (P), Golgi apparatus (G) and endoplasmic reticulum (E) fractions by discontinuous sucrose gradient centrifugation and examined for the expression of EAAT2 and Na + /K + ATPase α1 (a marker for plasma membraneassociated proteins) in each of these fractions by immunoblotting. The EAAT2 fractionation profiles were similar between transgenic and nontransgenic forebrain samples (Fig. 2D) indicating that the transgenic c-Myc-hEAAT2 was properly targeted to the plasma membrane. and nontransgenic cultures could not be made after 3 hr since the LDH release in glutamatetreated nontransgenic cultures appeared to reach plateau. These results suggest that overexpression of c-Myc-hEAAT2 protect cultured cells from glutamate-induced cytotoxicity.
We also determined the effect of overexpression of c-Myc-hEAAT2 on glutamate- were then examined for changes in motor performance, the onset of paralysis, body weight and life span. The ratio of males to females was constant for all populations. The SOD1(G93A)
transgene copy numbers and SOD1(G93A) protein expression levels were not different between G93A mice and G93A/EAAT2 mice as determine by Southern blot analysis and quantitative immunoblot analysis, respectively (data not shown). We first monitored motor performance using a rotorod but the mice could not be trained to remain on the rotorod. Instead, motor performance was assessed by measuring grip strength. There was no difference in grip strength between EAAT2 transgenic mice and their non-transgenic littermates (data not shown). The increased expression of hEAAT2 can improve motor performance but has no effect on the progression or the ultimate outcome of the disease in the G93A transgenic mouse model of ALS.
Increased expression of c-Myc-hEAAT2 partially protects motor neurons from SOD1(G93A)-mediated degeneration
To determine if increased expression of c-Myc-hEAAT2 would prevent the motor neuron loss observed in the G93A mice, we counted the number of motor neurons in the lumbar spinal cord of G93A transgenic, G93A/EAAT2 transgenic and non-transgenic mice at 90 days (early stage of disease progression) and 110 days (middle stage of disease progression) of age. As shown in Figure 6A and B, about 27.3% of the motor neurons were loss in G93A mice at 90 days of age days (compare EAAT2 to wildtype at 90 days). Motor neuron loss was not prevented, however, since most of the motor neurons in the G93A/EAAT2 transgenic mice were lost at ~130 days (late stage of the disease, data not shown).
We also assessed the effect of c-Myc-hEAAT2 overexpression on axonal degeneration observed in the spinal cord of G93A mice. As shown in Figure 6C , degeneration of axons in the ventral root of the spinal cord was evident at 90 days of age in G93A mice and most of the showed that glutamate uptakes were decreased as disease progression in G93A transgenic mice but were not significantly changed in G93A/EAAT2 mice (Fig. 7C) . These results indicated that our G93A/EAAT2 mice overexpressed functional transgenic EAAT2 protein during the disease process.
GFAP immunostaining, a marker for reactive gliosis, was not significantly different between G93A and G93A/EAAT2 mice suggesting that increased expression of EAAT2 does not affect gliosis observed in ALS ( Fig. 8A and B ).
Consistent with previous findings (10), we also observed an increase in the amount of mutant SOD1 in both G93A and G93A/EAAT2 mice during the disease process but the increase was less extent in G93A/EAAT2 transgenic mice when compared to G93A mice as determined by quantitative immunoblot analysis under reducing conditions and immunofluorescent staining ( Fig. 8A and B ). Immunoblot analysis under non-reducing conditions showed an increase in higher molecular weight (>200-kDa) forms of SOD1-immunoreactive protein ( forms of SOD1 aggregates that could not enter the gel in G93A mice. These results suggest that increased expression of EAAT2 reduces in the formation of high molecular weight forms of SOD1 aggregates.
For the quantitation of activated caspase-3 levels, we could not obtain reliable results by immunoblot analysis. Quantitative analysis of immunofluorescent staining showed that activated caspase-3 immunoreactivity was statistically significantly reduced (by ∼30%, p<0.01) in the lumbar spinal cord of G93A/EAAT2 transgenic mice when compared to G93A mice at 110 days (Fig. 8C) . The result was analyzed from 40 motor neurons. Taken together, these results suggest that increased expression of c-Myc-hEAAT2 reduces SOD1(G93A)-induced SOD1 aggregation and caspase-3 activation but not reactive gliosis.
DISCUSSION
In this study we have generated transgenic mice expressing EAAT2 under the control of the GFAP promoter and then crossed these mice with the ALS-associated mutant SOD1(G93A) mice to investigate whether supplementation of the loss of EAAT2 that occurs during the disease progression would delay or rescue the disease progression. Our EAAT2/G93A double transgenic mice showed a delay (14 days) in grip strength decline but not in the onset of paralysis, body weight decline or life span when compared to G93A littermates. We also observed a delay in the loss of motor neurons and their axonal morphologies as well as other events including caspase-3 activation and SOD1 aggregation in our EAAT2/G93A mice. This study suggests that the loss of EAAT2 may contribute to, but does not cause, motor neuron degeneration in ALS.
In order to detect transgenic EAAT2 protein expression, we placed a c-Myc epitope tag on N-terminus of EAAT2. However, expression of c-Myc-EAAT2 could not be detected by immunoblotting using anti-c-Myc antibodies obtained from different sources. We believe that it is due to poor antigenicity on N-terminus of EAAT2 protein based on the following observations: (1) we barely detected c-Myc-EAAT2 in HEK293 cells transfected with pcDNA3-c-Myc-EAAT2 using anti-c-Myc antibodies, (2) we also hardly detected EAAT2 with an Nterminal hemagglutinin (HA) epitope tag using anti-HA antibodies in the transfected HEK293 cells, (3) a rabbit polyclonal antibody directed against N-terminus of EAAT2 cannot easily bind to its antigen (unpublished observations). Nevertheless, we were able to detect c-Myc-EAAT2 by immunohistochemistry using anti-c-Myc antibodies (Fig. 2B) . Most importantly, c-Myc-hEAAT2 protein has normal cellular localization and glutamate transport activity as demonstrated in the cultured cells (data not shown) and in the mice ( Fig. 2 and 3 ).
The promoter of the human GFAP gene was used in this study to drive expression of the cMyc-EAAT2 transgene. Interestingly, we observed embryonic lethality or developmental delay and shortened lifespans in the F0 founder mice that carried high copy numbers of the transgene.
EAAT2 mRNA is expressed at low levels during the late stages of embryonic development and is significantly increased during postnatal development of the CNS (31). GFAP and reporter genes under the control of the GFAP promoter are expressed during mid-embryonic development (26) . Furthermore, ectopically expressed EAAT2 driven by the ubiquitous CMV promoter is toxic to undifferentiated primary astrocytes (32). It is possible, therefore, that inappropriate expression of EAAT2 during development may be detrimental to astrocytes as well as neurons.
Further studies will reveal the role of development on the expression of EAAT2 in astrocytes.
One interesting observation from this study is that the expression of the α1 subunit of the Na + /K + -ATPase was decreased in the EAAT2 transgenic mice (Fig. 2D) . It has been shown that glutamate uptake stimulates Na Functional knockdown of EAAT2 using antisense oligonucleotides resulted in excitotoxic neurodegeneration in the hippocampus and striatum of rats (15) . Furthermore, antisense knockdown of EAAT2 increased the severity of neuronal injury induced by focal cerebral ischemia and traumatic brain injury (38, 39) . We have shown in this study that increased EAAT2
protein expression protects neurons from the toxic effects of glutamate in primary dissociated cortical cultures derived from transgenic mice (Fig. 4) . These studies strongly suggest the importance of EAAT2 function in protecting neurons from excessive levels of extracellular glutamate. The mechanisms by which EAAT2 exerts its protective effect against excitotoxic damage remain to be elucidated.
The loss of functional EAAT2 has been observed in ALS patients as well as in animal models of ALS (18, 24, 25) . However, some groups have reported that EAAT2 levels are unchanged in mice expressing SOD1(G93A) protein (40) and that EAAT2 does not play an early and primary role in the SOD1(G93A)-induced motor neuron death (41). The role of EAAT2 in ALS, therefore, remains controversial. We crossed the EAAT2 transgenic mice with the SOD1(G93A) transgenic mice to investigate whether supplementation of the loss of EAAT2 in G93A mice can delay or rescue the disease progression. We have demonstrated that the G93A/EAAT2 double transgenic mice showed a statistically significant (14 days) delay in grip strength decline when compared to G93A littermates (Fig. 5) decline was not due to a nonspecific effect of overexpression of c-Myc-hEAAT2 since there were no differences in grip strength observed between EAAT2 transgenic mice and nontransgenic littermates. One may argue that this delay could potentially be due to a strain effect since the EAAT2 mice were generated in the FVB strain and crossed to the G93A mice in the SJL/BL6 hybrid background. We cannot exclude this possibility in the present study. However, the mice used in this study were littermates, which minimize the genomic background difference.
Furthermore, we used a large number of mice and two transgenic lines in this study to strengthen the results. If the observed protective results were due to a strain effect, then our study could suggest that supplementation of the loss of EAAT2 in G93A mice cannot change the disease progression and the loss of EAAT2 may be a secondary event resulting from motor neuron degeneration.
We did not observe significant difference in the onset of paralysis, decline of body weight and lifespan between the G93A/EAAT2 mice and the G93A mice in this study ( The most encouraging result in this study is that our EAAT2/G93A mice showed a delay in the loss of motor neurons and their axonal morphologies (Fig. 6) . These results not only support our grip strength study and also suggest that EAAT2 may play a role in preventing the early stage of SOD1(G93A)-induced motor neuron degeneration. EAAT2 may protect motor neurons from degeneration by reducing glutamate excitotoxicity or by other unknown mechanisms, which will be investigated in the future.
Bendotti et al. (24) have shown that the loss of EAAT2 in G93A mice was specifically found in 14-and 18-week-old mice that had motor function impairment, motor neuron loss and reactive astrocytosis. No changes in EAAT2 were observed at 8 weeks of age, i.e. before the appearance of clinical symptoms. Decreases in EAAT2 were accompanied by increased GFAP levels. We also observed the same phenomenon in this study. Interestingly, our EAAT2 transgene was driven by the GFAP promoter; the EAAT2 protein levels in G93A/EAAT2 mice were gradually increased as GFAP levels elevated during the disease progression (Fig. 7) . The lost EAAT2 were supplemented with even more transgenic EAAT2 (Fig. 7) . If the hypothesis that loss of EAAT2 leads to an increase of extracellular glutamate level and subsequent neurodegeneration is a primary contributor to disease progression, one could expect to see more profound protective effects. It is notable that the glutamate concentration in the cerebrospinal fluid (CSF) of G93A mice was not modified during the disease progression (24) . It is possible that loss of EAAT2 is a secondary event to the motor neuron degeneration. One hypothesis could be that the surrounding Southern blot analysis of Pst I-digested tail genomic DNA using a digoxygenin-labeled hEAAT2 cDNA probe as described previously (32). Pst I-digested pGFAP/c-Myc-hEAAT2 was used to generate the standard curve.
RT-PCR
Total RNA from mouse brain, spinal cord and other tissues was isolated with TRIzol (Invitrogen;
Grand Island, NY) and first-strand cDNA was synthesized with M-MLV reverse transcriptase (Invitrogen) and an EAAT2-specific primer (5'-gga tcc aga ctc ata tcc tta ttt ctc acg-3' 
[ 3 H] glutamate uptake assay
Uptake of radiolabeled glutamate was monitored in cultured cells and mouse brain synaptosomes as described previously (15, 47) . Transfected or cultured cells were grown on six-well plates and washed with uptake sample buffer (320 mM sucrose in 50 mM TrisHCl, pH 7.4) prior to uptake assays. For mouse synaptosomes, mouse brain tissue was homogenized in uptake sample buffer using a Dounce homogenizer and centrifuged at 1000×g for 10 min at 4°C to remove cellular debris. The supernatant (S1) was then centrifuged at 20,000×g for 30 min at 4°C and the resultant synaptosome pellet (P2) was resuspended in either Na 
Immunohistochemistry, Immunofluorescence and Histology
Fixation of mouse tissue and immunohistochemistry was accomplished as described previously For motor neuron counting, the L5 root of the spinal cord was dissected and fixed overnight with 4% paraformalehyde in PBS. After postfixing with osmium tetraoxide, roots were dehydrated and embedded in Epon812. Embedded roots were sectioned (1µm) and stained with toluidine blue. The morphology was examined under a light microscope.
Mouse Cortical Primary Cultures
Cortical neurons and astrocytes were cocultured from newborn (12-24 hours) nontransgenic and transgenic pups. The cortices were dissected out of the brains, incubated in activated papain for 30 min at 37°C, triturated by repeated pipetting with a small bore pipette and plated onto poly-Dlysine (1 mg/ml)-coated plastic culture dishes or glass slides. These cultures were maintained in Dulbecco's modified Eagle media (Invitrogen; Grand Island, NY) containing 25 mM glucose, 1 mM sodium pyruvate, 19.4 µM pyridoxine hydrochloride, 2 mM glutamine and 1% B-27 supplement (Invitrogen) until use.
Cell surface biotinylation
Labeling of proteins on the plasma membrane was accomplished by cell surface biotinylation as described previously (48). Cells were washed twice with PBS/CaMg (100 µM CaCl 2 and 1 mM The avidin beads were recovered by centrifugation (12, 000×g for 5 min at 4°C) and then washed four times with Lysis Buffer. After washing, the beads were resuspended in 1×Reducing SDS dye.
Subcellular fractionation
Plasma membrane, Golgi apparatus and endoplasmic reticulum fractions were isolated from adult mouse forebrains by discontinuous sucrose gradient centrifugation (49). Briefly, samples minutes. LDH release in treated cells was expressed relative to total LDH release.
Bis-benzimide Staining
Mouse cortical primary cultures were grown on glass coverslips and were processed as described 
Statistical Analysis
The quantitative data in this study were expressed as the mean ± SEM. Statistical analysis was performed using the unpaired Student's t-test and the ANOVA. 
ACKNOWLEDGMENTS
